文献速递乳房整形与再造

乳房扩张器/假体感染广谱抗生素治疗:不良事件与结局

Broad-Spectrum Antibiotics for Breast Expander/Implant Infection: Treatment-Related Adverse Events and Outcomes.
PubMed 文献 · Ann Plast Surg · 2021-01-01

该回顾性研究纳入101例患者(111次治疗发作),分析静脉广谱抗生素治疗乳房假体周围感染的方案、不良事件及假体挽救结局。

要点

  • 4%治疗发作因严重不良事件停药,其中3例最终取出假体。

核心结论

  • 静脉广谱抗生素治疗乳房假体周围感染结局较好且不良事件可耐受。
  • 应尽量降阶梯治疗(缩窄谱或限制疗程)以减少不良事件和细菌耐药。

研究设计与样本

  • 回顾性研究,纳入因假体周围感染接受静脉抗生素治疗的患者101例(111次治疗发作)。

主要发现

  • 平均抗生素治疗时长18天(范围1-40天)。
  • 最常用肠外方案为达托霉素联合哌拉西林-他唑巴坦(65%)或其他替代药物(16%)。
  • 无患者发生艰难梭菌结肠炎;5次治疗发作(4%)因严重不良事件需停用抗生素,其中3例取出假体。

临床怎么用

  • 治疗乳房假体周围感染时可考虑静脉广谱抗生素作为挽救假体的非手术方案。
  • 用药期间需监测不良事件,严重时可能需停药并评估取出假体。
  • 应尽量缩窄抗生素谱或限制疗程以降低不良事件和耐药风险。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite best practices, infection remains the most common complication after breast reconstruction with expanders and implants, ranging from 2% to 29%. Empiric broad-spectrum antibiotics are frequently used in nonsurgical treatment of implant-associated infections in an effort to salvage the reconstruction. Pitfalls of antibiotherapy include adverse events, vascular access site complications, and drug resistance. Our goals were to describe management of implant infections with broad-spectrum antibiotics, review treatment related adverse events, and report on outcomes of therapy. PATIENTS AND METHODS: A retrospective review was carried out to identify patients who were treated with intravenous (IV) antibiotics for periprosthetic infection. Patient characteristics, surgical details, and antibiotic therapy-related adverse events were collected. Eventual outcome related to expander/implant salvage was noted. RESULTS: A total of 101 patients (111 treatment episodes) were identified. Mean duration of antibiotic treatment was 18 days (range, 1-40 days). The most commonly used parenteral treatment was a combination of daptomycin with piperacillin-tazobactam (65%) or an alternative agent (16%). Fifty-nine percent of treatment episodes resulted in salvage of the expander or implant. Thirty-five percent treatment episodes were associated with 1 or more adverse events: diarrhea (12.6%), rash (10%), vaginal candidiasis (3.6%), agranulocytosis/neutropenic fever (3.6%), nausea (3.6%), urinary complaint (0.9%), myositis (0.9%), headache (0.9%), vascular line occlusion (1.8%), deep vein thrombosis (1.8%), and finger numbness (0.9%). No patients developed Clostridium difficile colitis. Five episodes (4%) needed discontinuation of antibiotics because of severe adverse events. The prosthesis was explanted in 3 of the cases of discontinued treatment. CONCLUSIONS: Our findings show favorable outcomes and well-tolerated adverse effects with broad-spectrum parenteral antibiotherapy for periprosthetic infection. However, every effort should be made to deescalate therapy by narrowing the spectrum or limiting the duration, to minimize adverse events and development of bacterial resistance. Treating surgeons need to carefully weigh benefits of therapy and be aware of potential complications that might necessitate discontinuation of treatment.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Ozturk CN, Ozturk C, Sigurdson SL, et al. Broad-Spectrum Antibiotics for Breast Expander/Implant Infection: Treatment-Related Adverse Events and Outcomes. Ann Plast Surg. 2021. PMID: 34559710. doi:10.1097/SAP.0000000000002720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。